Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Apr 3;156(7):512-24.
doi: 10.7326/0003-4819-156-7-201204030-00411. Epub 2012 Feb 27.

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies

Jonathan Hsu  1 , Nancy Santesso, Reem Mustafa, Jan Brozek, Yao Long Chen, Jessica P Hopkins, Adrienne Cheung, Gayane Hovhannisyan, Liudmila Ivanova, Signe A Flottorp, Ingvil Saeterdal, Arthur D Wong, Jinhui Tian, Timothy M Uyeki, Elie A Akl, Pablo Alonso-Coello, Fiona Smaill, Holger J Schünemann
Affiliations
Meta-Analysis

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies

Jonathan Hsu et al. Ann Intern Med. .

Abstract

Background: Systematic reviews of randomized, controlled trials in patients with influenza suggest a lack of evidence about the effects of antiviral therapy on several patient-important outcomes of influenza.

Purpose: To systematically review observational studies for benefits and harms of oseltamivir, zanamivir, amantadine, or rimantadine in the treatment of influenza.

Data sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, SIGLE, the Chinese Biomedical Literature Database, Panteleimon, and LILACS up to November 2010; contact with pharmaceutical companies; and reference lists.

Study selection: Observational studies in any language that compared single antiviral therapy with no therapy or other antiviral therapy, or that had no comparator, for influenza or influenza-like illness.

Data extraction: Two independent investigators extracted data. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Data synthesis: 74 studies fulfilled the inclusion criteria. Meta-analyses of the few studies providing effects with adjustment for confounders suggest that, in high-risk populations, oral oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI, 0.13 to 0.43]; low-quality evidence), hospitalization (odds ratio, 0.75 [CI, 0.66 to 0.89]; low-quality evidence), and duration of symptoms (33 hours [CI, 21 to 45 hours]; very low-quality evidence) compared with no treatment. Earlier treatment with oseltamivir was generally associated with better outcomes. Inhaled zanamivir may lead to shorter symptom duration (23 hours [CI, 17 to 28 hours]; moderate-quality evidence) and fewer hospitalizations (odds ratio, 0.66 [CI, 0.37 to 1.18]) but more complications than no treatment. Direct comparison of oral oseltamivir and inhaled zanamivir suggests no important differences in key outcomes. Data from 1 study suggest that oral amantadine may reduce mortality and pneumonia associated with influenza A. No included study evaluated rimantadine.

Limitations: Mortality was assessed in high-risk patients, and generalizability is limited. The overall body of evidence is limited by risk for confounding and selection, reporting, and publication bias.

Conclusion: Therapy with oral oseltamivir and inhaled zanamivir may provide a net benefit over no treatment of influenza. However, as with the randomized trials, the confidence in the estimates of the effects for decision making is low to very low. PRIMARY FUNDING SOURCES: World Health Organization and McMaster University.

PubMed Disclaimer

Figures

Appendix Figure.
Appendix Figure.
Summary of evidence search and selection.
Figure.
Figure.
Random-effects meta-analysis of oral oseltamivir versus no antiviral therapy based on studies that provided adjusted effect measures.
See this image and copyright information in PMC

Comment in

  • Antivirals for treatment of influenza.
    Jones MA, Hama R, Del Mar C. Jones MA, et al. Ann Intern Med. 2012 Sep 4;157(5):385; author reply 386-7. doi: 10.7326/0003-4819-157-5-201209040-00016. Ann Intern Med. 2012. PMID: 22944881 No abstract available.
  • Antivirals for treatment of influenza.
    Heneghan C, Jefferson T, Doshi P. Heneghan C, et al. Ann Intern Med. 2012 Sep 4;157(5):385-6; author reply 386-7. doi: 10.7326/0003-4819-157-5-201209040-00017. Ann Intern Med. 2012. PMID: 22944882 No abstract available.

References

    1. World Health Organization. State of the Art of Vaccine Research and Development. Geneva: World Health Organization; 2005. Accessed at www.who.int/vaccine_research/documents/Dip%20814.pdf on 17 February 2012
    1. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378:1917–30. - PubMed
    1. World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses. Geneva: World Health Organization; 2010. Accessed at www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_2009... on 17 February 2012. - PubMed
    1. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965. - PubMed
    1. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario, Canada: Ottawa Hospital Research Institute; 2011. Accessed at www.ohri.ca/programs/clinical_epidemiology/oxford.htm on 17 February 2012.

Publication types

MeSH terms